Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought

 
• By Sten Stovall

Novo Nordisk's GLP-1 franchise is advancing strongly and will be reinforced later this year by the expected approval of the ground-breaking oral semaglutide diabetes therapy, said CEO Lars Fruergaard Jørgensen

NovoNordisk
Novo Nordisk reported strong 1Q sales, with newly launched products Ozempic and Saxenda leading the way • Source: Shutterstock

More from Earnings

More from Business